VU Research Portal
Loss-of-function shRNA screens to identify mechanisms of PARP inhibitor resistance in BRCA1-mutated mouse mammary tumors
Xu, G.
2016
document version
Publisher's PDF, also known as Version of record
Link to publication in VU Research Portal
citation for published version (APA)
Xu, G. (2016). Loss-of-function shRNA screens to identify mechanisms of PARP inhibitor resistance in
BRCA1-mutated mouse mammary tumors.
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal ? Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
E-mail address:
vuresearchportal.ub@vu.nl
7
LIST OF ABBREVIATIONS
ACTB: β-actin A-TUB: α-tubulin
APC: anaphase-promoting complex/cyclosome; ATM: ataxia telangiectasia-mutated;
ATMi: ATM inhibitor;
BER: Base-excision repair;
BRCA1: Breast cancer type 1 susceptibility protein; BRCA2: Breast cancer type 2 susceptibility protein; BSA: bovine serum albumin;
CGH: comparative genomic hybridization; Chk1: Checkpoint kinase 1;
Chk2: Checkpoint kinase 2; CT: computed tomography;
CSR: Immunoglobulin class switch recombination DDR: DNA damage response;
DIDS: Detection of Imbalanced Differential Signal; DSBs: DNA double strand breaks;
DSBR: DNA double strand break repair; ES cells: embryonic stem cells;
FA: fanconi anaemia repair pathway; FCS: fetal calf serum;
gDNA: genomic DNA;
GEMM: genetically engineered mouse model; GFP: green fluorescent protein;
HELB: DNA helicase B;
HR: homologous recombination;
HRR: homologous recombination DNA repair; HRD: HR deficiencies;
HRP: horseradish peroxidase;
ICL: intra- or inter-strand cross-links;
8
IF: immunofluorescence; IR: ionizing radiation; K14: keratin14;
KB1P: K14Cre; Brca1F/F; p53F/F;
KB1PM: K14Cre; Brca1F/F; p53F/F; Mdr1-/-;
MAD2L2/REV7: MAD2 mitotic arrest deficient-like 2; MDR1/ABCB1: P-glycoprotein;
MEF: mouse embryonic fibroblast cell; MMR: Mismatch repair;
MTD: maximum tolerable dose; NER: nucleotide-excision repair; NHEJ: non-homologous end joining; PARP: poly (ADP-ribose) polymerase; PARPi: PARP inhibitor;
PBS: phosphate-buffered saline; PFA: Paraformaldehyde;
4′,6-diamidino-2-phenylindole (DAPI) P-gp: P-glycoprotein;
PIC: protease inhibitor cocktail; PI3K: phosphatidylinositol 3-kinase; PI3Ki: PI3K inhibitor;
Pol ζ: polymerase ζ
RNAseq: RNA sequencing; RPA2: replication protein A 2; RT: room temperature;
RT-qPCR: Quantitative reverse transcription PCR; SD: standard deviation;
SDS: sodium dodecyl sulfate;
SEM: the standard error of the mean; shRNA: short hairpin RNA ;
9
ssDNA: single-stranded DNA; TLS: Translesion DNA synthesis; TNBC: Triple negative breast cancer WB: western blot;
XRN2: 5'-3' Exoribonuclease 2;
